Prestige Consumer Healthcare (NYSE:PBH) Upgraded to “Buy” at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other equities analysts also recently weighed in on the company. Canaccord Genuity Group raised their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Finally, Royal Bank of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $89.24 on Friday. The stock has a market capitalization of $4.42 billion, a PE ratio of 20.90, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $90.04. The stock’s 50-day moving average price is $83.25 and its 200 day moving average price is $81.82. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.02 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new position in Prestige Consumer Healthcare in the first quarter valued at $277,000. Aristeia Capital L.L.C. purchased a new position in Prestige Consumer Healthcare in the first quarter valued at about $412,000. Goldman Sachs Group Inc. lifted its stake in shares of Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after purchasing an additional 120,965 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after purchasing an additional 1,289 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after purchasing an additional 3,200 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.